Do Traders Think CytoDyn Inc (CYDY) Can Keep Climbing Friday?

The market has been neutral on CytoDyn Inc (CYDY) stock recently. CYDY gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

CytoDyn Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on CYDY!

See Full CYDY Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CYDY Stock Today?

CytoDyn Inc (CYDY) stock is trading at $0.45 as of 12:12 PM on Friday, Jun 10, a drop of -$0.06, or -11.57% from the previous closing price of $0.51. The stock has traded between $0.45 and $0.50 so far today. Volume today is 1,940,012 compared to average volume of 1,589,887. To see InvestorsObserver's Sentiment Score for CytoDyn Inc click here.

More About CytoDyn Inc

CytoDyn Inc is a US-based clinical-stage biotechnology company which focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes on exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer. Click Here to get the full Stock Report for CytoDyn Inc stock.